Literature DB >> 31263944

T cells CD4+/CD8+ local immune modulation by prostate cancer hemi-cryoablation.

Michael A Cerqueira1, Karen L Ferrari1, Amilcar C de Mattos1, Carlos R Monti1, Leonardo Oliveira Reis2.   

Abstract

PURPOSE: Tumors escape from the immune system by decreasing CD8+ and increasing CD4+ T cells' activity, druggable targets. Thermal ablation might activate tumor-specific T cells by raising the presentation of tumor-specific antigens and hindering tumor negative immune regulation. Our aim was to assess T cell infiltrate pre- and post-cryoablation in a prospective observational study.
METHODS: A total of 240 sextant prostate biopsies cores (12 cores/patient) were collected from 10 unilateral prostate cancer patients (T1c, PSA density < 0.15 ng/dL, Gleason grade group 1, ≤ 2 cancer biopsy cores, and < 50% cancer core involvement) at diagnosis and 12 months after hemi-cryoablation. Cancer-positive (Diag+) and cancer-negative (Diag-) lobes at diagnosis and the same areas 12 months after hemi-cryoablation (Cryo+ and Cryo-, respectively) were explored by immunohistochemistry for infiltrating CD4+ and CD8+ T cells (in 45 random fields per prostate lobe, 400× magnification). The quantitative analysis of cells/mm2 and CD4+/CD8+ ratio were performed and compared among Diag+, Diag-, Cryo+, and Cryo- using ImageJ software.
RESULTS: There was a significant increase in tumor-infiltrating CD8+ T cells/mm2 in the Cryo+ tissue (mean, SD 0.31, 0.30) compared to Diag+ (0.18, 0.15), p = 0.015; confirmed in prostate acini (hot spots), p = 0.029, in which infiltrating CD4+/CD8+ T cells' ratio decreased after hemi-cryoablation, p = 0.006. Infiltrating CD4+ T cells/mm2 presented a trend to decrease in Cryo+ (0.26, 0.27) compared to Diag+ (0.38, 0.32).
CONCLUSIONS: This is the first study to show local immune modulation after prostate cancer cryoablation, characterized by decreasing CD4+/CD8+ T cells' ratio, potential for clinical impact by unleashing the T-cell response to cancer. Future studies are necessary to explore different energies and longer follow-up clinical endpoints.

Entities:  

Keywords:  Ablation; Prostate cancer; Tumor microenvironment; Tumor-infiltrating T cells

Mesh:

Year:  2019        PMID: 31263944     DOI: 10.1007/s00345-019-02861-0

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  21 in total

Review 1.  Visualization approaches for multidimensional biological image data.

Authors:  Curtis T Rueden; Kevin W Eliceiri
Journal:  Biotechniques       Date:  2007-07       Impact factor: 1.993

2.  Burden of focal cryoablation versus brachytherapy versus active surveillance in the treatment of very low-risk prostate cancer: a preliminary head-to-head comprehensive assessment.

Authors:  M A de Cerqueira; W W Laranja; B C F Sanches; C R Monti; L O Reis
Journal:  Eur J Cancer Care (Engl)       Date:  2015-03-05       Impact factor: 2.520

3.  Are 10-, 10-12-, or > 12-mm prostate biopsy core quality control cutoffs reasonable?

Authors:  Brunno C F Sanches; Ana Luiza Lalli; Wilmar Azal Neto; Athanase Billis; Leonardo Oliveira Reis
Journal:  World J Urol       Date:  2018-03-01       Impact factor: 4.226

4.  CD4 helper T cells, CD8 cytotoxic T cells, and FOXP3(+) regulatory T cells with respect to lethal prostate cancer.

Authors:  Sabina Davidsson; Anna-Lena Ohlson; Swen-Olof Andersson; Katja Fall; Allison Meisner; Michelangelo Fiorentino; Ove Andrén; Jennifer R Rider
Journal:  Mod Pathol       Date:  2012-10-05       Impact factor: 7.842

Review 5.  Histological outcomes after focal high-intensity focused ultrasound and cryotherapy.

Authors:  Taimur T Shah; Veeru Kasivisvanathan; Charles Jameson; Alex Freeman; Mark Emberton; Hashim U Ahmed
Journal:  World J Urol       Date:  2015-05-06       Impact factor: 4.226

6.  The relationship between T-lymphocyte subset infiltration and survival in patients with prostate cancer.

Authors:  P A McArdle; K Canna; D C McMillan; A-M McNicol; R Campbell; M A Underwood
Journal:  Br J Cancer       Date:  2004-08-02       Impact factor: 7.640

7.  Immunotherapy: shifting the balance of cell-mediated immunity and suppression in human prostate cancer.

Authors:  Jo A Tucker; Caroline Jochems; James L Gulley; Jeffrey Schlom; Kwong Y Tsang
Journal:  Cancers (Basel)       Date:  2012-12-11       Impact factor: 6.639

8.  Peripheral lymphocyte subset variation predicts prostate cancer carbon ion radiotherapy outcomes.

Authors:  Zhang-Ru Yang; Ning Zhao; Jin Meng; Ze-Liang Shi; Bing-Xin Li; Xian-Wei Wu; Ping Li; Qing Zhang; Xun-Bin Wei; Shen Fu
Journal:  Oncotarget       Date:  2016-05-03

9.  FOXP3+ regulatory T cells in normal prostate tissue, postatrophic hyperplasia, prostatic intraepithelial neoplasia, and tumor histological lesions in men with and without prostate cancer.

Authors:  Sabina Davidsson; Ove Andren; Anna-Lena Ohlson; Jessica Carlsson; Swen-Olof Andersson; Francesca Giunchi; Jennifer R Rider; Michelangelo Fiorentino
Journal:  Prostate       Date:  2017-11-06       Impact factor: 4.104

10.  A Unique Cellular and Molecular Microenvironment Is Present in Tertiary Lymphoid Organs of Patients with Spontaneous Prostate Cancer Regression.

Authors:  María de la Luz García-Hernández; Norma Ofelia Uribe-Uribe; Ricardo Espinosa-González; W Martin Kast; Shabaana A Khader; Javier Rangel-Moreno
Journal:  Front Immunol       Date:  2017-05-17       Impact factor: 7.561

View more
  4 in total

Review 1.  Recent progress in cryoablation cancer therapy and nanoparticles mediated cryoablation.

Authors:  Kijung Kwak; Bo Yu; Robert J Lewandowski; Dong-Hyun Kim
Journal:  Theranostics       Date:  2022-02-14       Impact factor: 11.556

2.  An In Vitro Investigation into Cryoablation and Adjunctive Cryoablation/Chemotherapy Combination Therapy for the Treatment of Pancreatic Cancer Using the PANC-1 Cell Line.

Authors:  John M Baust; Kimberly L Santucci; Robert G Van Buskirk; Isaac Raijman; William E Fisher; John G Baust; Kristi K Snyder
Journal:  Biomedicines       Date:  2022-02-15

3.  Pulsed focused ultrasound can improve the anti-cancer effects of immune checkpoint inhibitors in murine pancreatic cancer.

Authors:  Petros X E Mouratidis; Marcia Costa; Ian Rivens; Elizabeth E Repasky; Gail Ter Haar
Journal:  J R Soc Interface       Date:  2021-07-07       Impact factor: 4.118

4.  Immune profiling of the bone marrow microenvironment in patients with high-risk localized prostate cancer.

Authors:  Erika Heninger; Nan Sethakorn; David Kosoff; Peiman Hematti; Morgan D Kuczler; Kenneth J Pienta; Joshua M Lang
Journal:  Oncotarget       Date:  2020-11-17
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.